Darly Milena Giraldo

Dr. Darly Milena Giraldo

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
GSGonzalo Sánchez-Benavides
Gonzalo Sánchez-Benavides
AIAlex Iranzo
Alex Iranzo
OGOriol Grau
Oriol Grau
DGDarly Milena Giraldo
Darly Milena Giraldo
MBMariateresa Buongiorno
Mariateresa Buongiorno
An abnormal accumulation of misfolded proteins is a common feature shared by most neurodegenerative disorders. Olfactory dysfunction (OD) is common in the elderly population and is present in 90% of patients with Alzheimer’s or Parkinson’s disease, usually preceding the cognitive and motor symptoms onset by several years. Early Aβ, tau, and α-synuclein protein aggregates deposit in brain structures involved in odor processing (olfactory bulb and tract, piriform cortex, amygdala, entorhinal cortex, and hippocampus) and seem to underly OD. The glymphatic system is a glial-associated fluid transport system that facilitates the movement of brain fluids and removes brain waste during specific sleep stages. Notably, the glymphatic system became less functional in aging and it is impaired in several conditions, including neurodegenerative diseases. As the nasal pathway has been recently described as the main outflow exit of cerebrospinal fluid and solutes, we hypothesized that OD may indeed be a clinical marker of early glymphatic dysfunction through abnormal accumulation of pathological proteins in olfactory structures. This effect may be more pronounced in peri- and postmenopausal women due to the well-documented impact of estrogen loss on the locus coeruleus, which may disrupt multiple mechanisms involved in glymphatic clearance. If this hypothesis is confirmed, olfactory dysfunction might be considered as a clinical proxy of glymphatic failure in neurodegenerative diseases.

19 July 2025 in Brain Sciences
Verified
Journal Article
Open access
PDF file
MBMariateresa Buongiorno
Mariateresa Buongiorno
CTCarmen Tur
Carmen Tur
DGDarly Milena Giraldo
Darly Milena Giraldo
NCNatalia Cullell
Natalia Cullell
JKJerzy Krupinski
Jerzy Krupinski
GSGonzalo Sánchez-Benavides
Gonzalo Sánchez-Benavides
Epidemiological studies identified insufficient and poor-quality sleep as independent risk factors for multiple sclerosis (MS). The glymphatic system, active during slow-wave sleep, clears brain waste through perivascular astrocytic aquaporin-4 (AQP4) channels. The presence of antigens induces a transient, physiological lowering of glymphatic flux as a first step of an inflammatory response. A possible hypothesis linking infection with the Epstein–Barr virus, a well identified causal step in MS, and the development of the disease is that mechanisms such as poor sleep or less functional AQP4 polymorphisms may sustain glymphatic flow reduction. Such chronic glymphatic reduction would trigger a vicious circle in which the persistence of antigens and an inflammatory response maintains glymphatic dysfunction. In addition, viral proteins that persist in demyelinated plaques can depolarize AQP4, further restricting waste elimination and sustaining local inflammation. This review examines the epidemiological evidence connecting sleep and MS risk, and the mechanistic findings showing how poor sleep and other glymphatic modulators heighten inflammatory signaling implicated in MS pathogenesis. Deepening knowledge of glymphatic functioning in MS could open new avenues for personalized prevention and therapy.

12 February 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
GSGonzalo Sánchez-Benavides
Gonzalo Sánchez-Benavides
AIAlex Iranzo
Alex Iranzo
OGOriol Grau
Oriol Grau
DGDarly Milena Giraldo
Darly Milena Giraldo
MBMariateresa Buongiorno
Mariateresa Buongiorno
An abnormal accumulation of misfolded proteins is a common feature shared by most neurodegenerative disorders. Olfactory dysfunction (OD) is common in elderly population and is present in 90% of patients with Alzheimer’s or Parkinson’s disease, usually preceding the cognitive and motor symptoms onset by several years. Early Aβ, tau and α-synuclein protein aggregates have been observed in brain structures involved in odor processing (olfactory bulb and tract, piriform cortex, amygdala, entorhinal cortex, and hippocampus) and seem to underly OD. Glymphatic system is a glial-associated fluid transport system that facilitates the movement of CSF and ISF and removes brain waste during specific brain waste sleep stages. Noteworthy, glymphatic system became less functional in aging and is impaired in several conditions, including neurodegenerative diseases. As the nasal pathway has been recently described as the main outflow pathway of cerebrospinal fluid and solutes, we hypothesized that OD may be indeed a clinical marker of early glymphatic dysfunction that entails abnormal accumulation of pathological proteins in olfactory structures. Here we review the physiological, anatomical, and chronological evidence supporting this suggestion. If this hypothesis is confirmed, olfactory dysfunction could be considered as a clinical proxy of glymphatic dysfunction in neurodegenerative diseases.

7 October 2025 in medRxiv
Verified
Preprint
Open access
PDF file
MBMariateresa Buongiorno
Mariateresa Buongiorno
NVNatalia Vilor-Tejedor
Natalia Vilor-Tejedor
BSBárbara Segura
Bárbara Segura
AIAlex Iranzo
Alex Iranzo
YCYaroslau Compta
Yaroslau Compta
GSGonzalo Sánchez-Benavides
Gonzalo Sánchez-Benavides
Background: Pathogenic mutations in the leucine-rich repeat kinase-2 ( LRRK2 ) gene are the most common cause of familial Parkinson’s disease (PD). LRRK2 shows incomplete penetrance, yet the biological factors influencing disease expression remain unknown. Objectives: To investigate whether genetic variants in aquaporin-4 ( AQP4 ), key in glymphatic system functioning, are associated with the penetrance of PD in LRRK2 carriers. Methods: We analyzed baseline data from 302 LRRK2 carriers from the Parkinson’s Progression Markers Initiative. Fourteen AQP4 single nucleotide polymorphisms, previously implicated in PD, Alzheimer’s disease, or other neurodegenerative-related processes were tested for association with PD manifestation using logistic regression models adjusted for age and sex. Recessive, dominant, and additive genetic models were explored. Sensitivity analyses were conducted in G2019S carriers (n=273). Results: One hundred twenty-seven (42%) LRRK2 carriers were asymptomatic, and 174 (58%) had PD. There were no differences between groups in age (63.5[9.5] vs. 62.2[7.5]) or number of women (52.0% vs. 55.7%). Homozygosity for the minor allele of rs9951307 was associated with reduced likelihood of PD (OR=0.28, 95% CI 0.10–0.64, p=0.005), whereas rs335930 homozygosity was associated with increased likelihood (OR=4.2, 95% CI 1.41–15.6, p=0.016). Additive models supported these associations, though rs335930 did not surpass the adjusted threshold. Results were consistent in the G2019S subgroup. Conclusions: AQP4 polymorphisms may contribute to the variable penetrance of LRRK 2 mutations, potentially though modulation of glymphatic clearance. These findings support the glymphatic system as a relevant pathway in familial PD and highlight AQP4 as a candidate therapeutic target.

11 February 2026 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
MAManuel Alanís-Bernal
Manuel Alanís-Bernal
LMLaura Melgarejo
Laura Melgarejo
LBLaia Boada-Oller
Laia Boada-Oller
Santiago RiosSantiago Rios
Santiago Rios
OMOlga Maisterra
Olga Maisterra
APAntonio Palasí
Antonio Palasí